Urologic Cancer Facts and Updates for World Cancer Day 2025

Credit: Adobe Stock

As World Cancer Day draws attention to global progress in cancer care, it also underscores the critical need for continued awareness of urologic cancers, including prostate, bladder, kidney, and testicular cancers.

Despite advancements in treatment, early detection through routine screenings remains a key factor in improving survival rates and patient outcomes. Examining the latest statistics, trends, and benefits of screening offers valuable insight into how proactive health measures can make a significant difference in the fight against these cancers.

In recognition of World Cancer Day 2025, Urology Times has compiled a list of statistics, trends, and information on the observed benefits of screening for 4 different forms of urologic cancers.

Urologic Cancer Facts and Updates: World Cancer Day 2025

Prostate Cancer:

• Statistics: Prostate cancer is the most common urologic cancer, with over 288,300 new cases expected in the US in 2024, accounting for approximately 34,700 deaths annually.
• Trends: Prostate cancer incidence has fluctuated with changes in screening practices, showing a 3% annual increase from 2014 to 2019.
• Benefit of Screening: PSA screening can reduce the risk of prostate cancer death by up to 20% in men aged 55–69, according to clinical trial data.

Bladder Cancer:

• Statistics: Bladder cancer is the sixth most common cancer in the US, with an estimated 82,290 new cases and 16,710 deaths projected in 2024.
• Trends: Bladder cancer incidence rates have been stable overall but are declining among women, partly due to reduced smoking rates.
• Benefit of Screening: Early detection through urine cytology and cystoscopy can improve 5-year survival rates to 77% when diagnosed at an early stage, compared to 5% for advanced cases.

Kidney Cancer:

• Statistics: Approximately 81,610 new cases of kidney cancer are expected in 2024, with a higher prevalence in men than women.
• Trends: Kidney cancer incidence has risen by 2% annually over the past decade, likely due to increased imaging and earlier detection.
• Benefit of Screening: While routine screening is not standard, incidental detection through imaging can lead to early-stage diagnoses with a 5-year survival rate of 93%.

Testicular Cancer:

• Statistics: Testicular cancer is relatively rare, with around 9,190 new cases expected in 2024, but it is the most common cancer in men aged 15–35.
• Trends: Incidence rates have been rising slightly, but mortality rates remain low due to effective treatments.
• Benefit of Screening: Regular self-exams and prompt medical attention for abnormalities contribute to early detection, with a 5-year survival rate exceeding 95% when caught early.

References:

1. American Cancer Society. Cancer Facts & Figures 2024. Atlanta, GA: American Cancer Society; 2024.

2. National Cancer Institute. SEER Cancer Statistics. Available at: https://seer.cancer.gov/. Accessed January 2024.

3. United States Preventive Services Task Force. Prostate Cancer: Screening. Available at: https://www.uspreventiveservicestaskforce.org/. Accessed January 2024.

4. Centers for Disease Control and Prevention. Urologic Cancers: Facts and Statistics. Available at: https://www.cdc.gov/cancer/. Accessed January 2024.

5. Bladder Cancer Advocacy Network. Bladder Cancer Statistics. Available at: https://www.bcan.org/. Accessed January 2024.